Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

Ensuring Quality Assurance in Life Sciences: Best Practices and Strategies

Apr 25, 2025

Introduction to Quality Assurance in Life Sciences

In the life sciences industry, quality assurance (QA) is paramount to ensuring the safety and efficacy of products. Whether it's pharmaceuticals, biotechnology, or medical devices, maintaining high-quality standards is crucial. Quality assurance provides the framework for consistently delivering products that meet regulatory requirements and customer expectations.

quality control laboratory

Understanding the Importance of QA

Quality assurance in life sciences is not just about compliance; it's about building trust with consumers. When a product is released to the market, it should be safe for use and perform its intended function effectively. This is achieved through a series of rigorous testing and validation processes.

The stakes are incredibly high, as any lapse in quality can lead to severe consequences, including product recalls, legal ramifications, and damage to a company's reputation. Therefore, implementing a robust QA system is not optional but essential.

Best Practices in Quality Assurance

To ensure effective QA, life sciences companies should adopt several best practices:

  1. Standard Operating Procedures (SOPs): Develop clear and detailed SOPs to guide all processes and ensure consistency.
  2. Continuous Training: Regularly train employees to stay updated with the latest QA standards and technologies.
  3. Document Control: Maintain meticulous records of all QA activities for transparency and traceability.
employee training life sciences

Strategies for Effective Implementation

Implementing a successful QA program involves strategic planning and execution. One effective strategy is to integrate quality assurance early in the product development lifecycle. This proactive approach ensures that potential issues are identified and addressed before they escalate.

Another strategy involves leveraging technology to enhance QA processes. Utilizing advanced software solutions can automate routine tasks, reduce human error, and provide real-time data analytics for better decision-making.

The Role of Regulatory Compliance

Regulatory compliance is a critical component of quality assurance in life sciences. Organizations must adhere to guidelines set by regulatory bodies such as the FDA, EMA, and other local authorities. Staying compliant requires ongoing monitoring of regulatory changes and timely updates to processes and documentation.

regulatory compliance

Challenges and Solutions

The dynamic nature of the life sciences industry presents several challenges to maintaining quality assurance. These include evolving regulations, technological advancements, and increasing competition. To address these challenges, companies should foster a culture of continuous improvement and innovation.

Investing in research and development can help organizations stay ahead of industry trends and improve their QA systems. Additionally, collaborating with industry peers and participating in professional forums can provide valuable insights and resources.

Conclusion

Ensuring quality assurance in life sciences requires a comprehensive approach that combines best practices, strategic planning, and adherence to regulatory standards. By prioritizing quality at every stage of the product lifecycle, companies can safeguard their reputation, meet consumer expectations, and contribute positively to public health.

life sciences innovation